Jordi Xiol spent over a decade in biomedical research, including a PhD at EMBL Grenoble and a postdoc at Harvard, and published lead-author papers in Cell and Cell Stem Cell before becoming a partner at Ysios Capital, where he built his investing skills partly by teaching himself the market through public biotech stocks. He now combines that scientific background with a close look at how a therapy could actually reach patients, talking with clinicians, manufacturing experts, IP lawyers, and bankers, while also serving as Lead Advisor to Telescope Biotech Fund, connecting private and public biotech investing.
About their Fund
Ysios Capital is Spain's largest life sciences venture capital firm, with ties to Spain's science leadership through cofounder Cristina Garmendia, who left the firm to serve as Spain's Minister of Science and Innovation before returning as a partner, and it has moved beyond typical venture investing into company creation through its InceptionBio vehicle, which builds biotech companies from early tech-transfer projects with a strong focus on Spain. The firm focuses on hard science areas like gene therapy, oncology, orphan CNS disease, calcification disorders, and regenerative cardiovascular implants, has backed deals such as Sanifit's acquisition by Vifor Pharma and U.S.-based Kala Pharmaceuticals, and produced three NASDAQ IPOs in 2021 alongside its oversubscribed €216M third fund.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































